Related Experiment Video

Updated: Mar 13, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Prostate cancer: Targeting apoptosis resistance in CRPC

Clemens Thoma

    Nature Reviews. Urology
    |October 12, 2016
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
    12:13

    Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

    Published on: November 19, 2019

    7.3K
    Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
    06:44

    Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

    Published on: September 8, 2017

    14.1K

    Related Experiment Videos

    Last Updated: Mar 13, 2026

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    14.0K
    Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
    12:13

    Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

    Published on: November 19, 2019

    7.3K
    Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
    06:44

    Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

    Published on: September 8, 2017

    14.1K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    9.1K
    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.1K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    3.9K
    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.9K

    Articles linked to this work by shared authors, journal, and citation graph.

    Unconventional T cells in urological cancers: catch them if you can.

    Nature reviews. Urology·2026

    Integrating clinically actionable biomarkers into bladder cancer care - recommendations from the International Bladder Cancer Group.

    Nature reviews. Urology·2026

    The urinary microbiome, overactive bladder and bladder pain syndrome/interstitial cystitis - mechanisms, diagnostics and therapeutic opportunities.

    Nature reviews. Urology·2026

    Neoadjuvant intraprostatic immunotherapy for high-risk localized prostate cancer.

    Nature reviews. Urology·2026

    The role of CFTR in spermatogenesis and sperm quality.

    Nature reviews. Urology·2026

    Urolithiasis in patients with cancer.

    Nature reviews. Urology·2026

    Assessment of Natural Killer Cell Serial Degranulation.

    Current protocols·2026

    Oncogenic KRAS Rewires mRNA Stability and Translation through AGO2-Mediated Disruption of the miRNA pathway.

    Cancer research·2026

    Stimuli-responsive nanocarriers for precision cation channel therapy.

    Chemical communications (Cambridge, England)·2026

    Disruption of hippocampal upstream regulators of mTOR and insulin pathways in Down syndrome with Alzheimer's disease neuropathology: Preliminary observations.

    Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

    ATF7 drives diabetic wound healing via NOTCH1 repression and N1ICD-dependent macrophage polarization control.

    JCI insight·2026

    Innate immune sensor NOD2 promotes cartilage degradation and osteoarthritis progression by stabilizing TRAF6 in chondrocytes.

    JCI insight·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us